IATDMCT Congress 2017 Poster Presentations

To get the latest update, please clear or refresh your web browser's cache.
*i.e. Google Chrome: Ctr + F5 keys

P26-1: Anticonvulsant drugs

# Presentation Title Name Country Affiliation
1 Volumetric absorptive microsampling as an alternative tool for therapeuticdrug monitoring of first-generation anti-epileptic drugs Sofie Velghe Belgium Ghent University
2 Development and validation of a dried blood spot method for routinetherapeutic drug monitoring of common antiepileptic drugs Camilla HannaLinder Sweden Karolinska University Laboratory andKarolinska Institutet
3 Automated preparation and analysis of a large range of antiepilpetics fortherapeutic drug monitoring by LC-MS/MS Mikael Levi Japan Shimadzu Corporation
4 Development and validation of phenytoin quantification from humanbrain, CSF and plasma by liquid chromatography tandem massspectrometry Neha Dhir India Postgraduate Institute of MedicalEducation and Research (PGIMER)
5 Quinidine in epilepsy: TDM to improve therapy in migrant partial seizuresof infancy Maria CeciliaKravetz Argentina Universidad de Buenos Aires
6 Levetiracetam dosing Maria Outeda-Macias Spain A Coruna University Hospital Complex
7 A population pharmacokinetic-pharmacodynamic analysis of valproic acidin pediatric patients with epilepsy Junji Saruwatari Japan Kumamoto University
8 Pharmacokinetic drug interactions with valproate and antiepileptic orantipsychotic drugs ?still a mystery after 50 years? Tore Haslemo Norway Diakonhjemmet Hospital
9 Population pharmacokinetic analysis of phenytoin after intravenousadministration of fosphenytoin in Japanese epileptic patients Daiki Yamashita Japan Fukuoka Tokushukai Medical Center

P26-2: Central nervous system drugs (1)

# Presentation Title Name Country Affiliation
1 Phenobarbital pharmacokinetics during therapeutic hypothermia afterperinatal asphyxia: evaluation of an existing model Laurent Favie TheNetherlands University Medical Center Utrecht
2 Lidocaine pharmacokinetics during therapeutic hypothermia afterperinatal asphyxia: evaluation of an existing model Laurent Favie TheNetherlands University Medical Center Utrecht
3 Population pharmacokinetic modeling and simulation of topiramate usingthe routinely monitored data for the individualized dosage adjustment Masato Takeuchi Japan Kyoto University Hospital
4 Clinical validation of a dried blood spot method for determination ofrisperidone, aripiprazole, pipamperone and their major metabolites SanneKloosterboer TheNetherlands Erasmus MC
5 Evaluation of thermo scientific CEDIA Buprenorphine II assay David WilliamKinniburgh Canada University of Calgary
6 Simultaneous quantification of perampanel and nine newer antiepilepticdrugs in human serum using ultra performance liquid chromatographymass spectrometry detection DaisukeKobayashi Japan Kyushu University
7 Fully automatized LC-MS/MS analysis of neuroleptics using a novel samplepreparation system Stephane Moreau Germany Shimadzu Europa GmbH
8 Evaluation the influence of ten interference drugs of lithium determinationin atomic absorption spectroscopy and colorimetric method Wei Guo China Beijing Anding Hospital, Capital MedicalUniversity
9 Effect of lipid emulsion infusion on paliperidone pharmacokinetics in theacute overdose rat model: a potential emergency treatment forpaliperidone intoxication TomoyukiEnokiya Japan Mie University Hospital

P26-3: Central nervous system drugs (2)

# Presentation Title Name Country Affiliation
1 Acute cholinergic syndrome observed with the use of cholinesteraseinhibitors in two patients with Alzheimer's type dementia TomokiHanazawa Japan Saitama Medical University Hospital
2 Suspected criminal use of flunitrazepam tablets: a case report TomohiroYoshizawa Japan Saitama Medical University Hospital
3 ARK fentanyl assay for the Siemens Viva-E automated clinical chemistryanalyzer Byung Moon United States ofAmerica ARK Diagnostics Inc.
4 Inflammation increased serum clozapine concentrations: two casesreports Can-Jun Ruan China Beijing Anding Hospital, Capital MedicalUniversity
5 Necessity of measurement of serum levetiracetam level in patients withnormal renal function for effective medication Hiroyuki Manshio Japan Anjo Kosei Hospital
6 Effectiveness of barbiturate therapy for severely increased intracranialpressure based on pharmacokinetic analysis YukakoYamakawa Japan Kumamoto University Hospital
7 Association between 5-HTR2C -759C/T (rs3813929) and -697G/C(rs518147) gene polymorphisms and risperidone-induced metabolicsyndrome in Indian population Saibal Das India Christian Medical College, Vellore
8 Influence of the cytochrome P450 2D6 polymorphisms on thepharmacokinetics of paroxetine in Japanese patients with majordepressive disorder: a population pharmacokinetic analysis Kazuma Iwashita Japan Kumamoto University
9 Determination of fluvoxamine in biological fluids Fazliddin Jalilov Uzbekistan Tashkent Pharmaceutical Institute

P26-4: Central nervous system drugs (3)

# Presentation Title Name Country Affiliation
1 Comparison of reduced function CYP2D6 alleles on venlafaxine andrisperidone metabolic ratios Tore Haslemo Norway Diakonhjemmet Hospital
2 Clinical evaluation of lithium with tubular reabsorption mechanisms andurinary pH based on hospital pharmacometrics Daichi Yamaguchi Japan University of Toyama
3 The estimation of pharmacokinetic parameters of lithium in children bypharmacokinetic modeling: a pilot study at Yuwaprasart WaithayopathumChild Psychiatric Hospital KarunratTewthanom Thailand Silpakorn University
4 Should older patients have lower serum lithium therapeutic ranges? Lei Fu Canada Sunnybrook Health Sciences Centre andUniversity of Toronto
5 Neonatal abstinence syndrome after in utero exposure to antidepressantand benzodiazepines MariadelfinaMolinaro Italy Fondazione IRCCS Policlinico San Matteo
6 The effectiveness of phenobarbital in patients with refractory statusepilepticus undergoing therapeutic plasma exchange Chunping Gu China Nanfang Hospital, Southern MedicalUniversity
7 Efficacy of Levetiracetam and necessary of serum drug concentrationmeasuring in epilepsy therapy: a preliminary study DenpongPatanasethanont Thailand Khon Kaen University
8 Safety and pharmacokinetics of 2-iminobiotin in neonates with therapeutichypothermia after perinatal asphyxia Laurent Favie TheNetherlands University Medical Center Utrecht
9 A pharmacodynamic model of midazolam-induced sedation in terminallyill adult patients Birgit C. P. Koch TheNetherlands Erasmus MC

P26-5: Immunosuppressive drugs (4): Individualized dosage adjustment

# Presentation Title Name Country Affiliation
1 Overweight kidney transplant recipients are at risk of being overdosedfollowing standard bodyweight-based tacrolimus dosing Louise M.Andrews TheNetherlands Erasmus MC
2 Prolongation of biologic dosing intervals in patient with stable psoriasis; afeasibility study Teun van Gelder TheNetherlands Erasmus MC
3 Overweight and underweight kidney transplant recipients at risk of beingunderdosed or overdosed following standard tacrolimus dosing Jiang-Tao Tang China West China Hospital of Sichuan University
4 Twenty-four hour tacrolimus pharmacokinetics in renal transplantrecipients on twice-daily dosing Marte TheieGustavsen Norway Oslo University Hospital Rikshospitalet
5 High tacrolimus clearance and acute rejection risk after renaltransplantation ErlendJohannessenEgeland Norway University of Oslo
6 Survival time to biopsy-proven acute rejection in pediatric liver transplantpatients Natalia Riva Argentina Hospital de Pediatria JP Garrahan
7 Sublingual tacrolimus administration: experience in pediatric livertransplant patients Natalia Riva Argentina Hospital de Pediatria JP Garrahan
8 Relationship between exposure to tacrolimus, adherence and quality oflife in kidney transplant recipients CarolineMonchaud France CHU Limoges, Univ Limoges
9 Relationship between tacrolimus exposure and adverse effects over timein renal transplantation CarolineMonchaud France CHU Limoges, Univ Limoges
10 Sequential tacrolimus trough monitoring during the first month of renaltransplantation Susan Binu Philip India Christian Medical College

P26-6: Immunosuppressive drugs (5): Clinical practice

# Presentation Title Name Country Affiliation
1 Evaluation of the conversion from Advagraf to Envarsus in stable kidneytransplant patients Patricio Mas-Serrano Spain Hospital General Universitario de Alicante
2 MeltDose tacrolimus clinical pharmacokinetics in adult renal transplantrecipients in the early transplant period Pilar Salvador-Garrido Spain A Coruna University Hospital Complex
3 Prediction of cyclosporine A blood concentration with voriconazole usingSimcyp Simulator: case report Masahiro Moriya Japan Tokyo Women's Medical UniversityHospital
4 Therapeutic drug monitoring improves efficacy of cyclosporine A inaplastic anemia patients Wangjun Qin China China-Japan Friendship Hospital
5 Clinical pharmacokinetics of mycophenolic acid: a comparison betweenthe two formulations of mycophenolate mofetil (Cellcept and Myfenax)and the enteric-coated mycophenolate sodium (Myfortic) in adult renal Pilar Salvador-Garrido Spain A Coruna University Hospital Complex
6 Population pharmacokinetics and its clinical application of MycophenolateMofetil in renal transplantation patients Li-Qin Tang China Anhui Provincial Hospital
7 Therapeutic drug monitoring of everolimus depends on concomitantimmunosuppressant in heart transplant patients ? preliminarypharmacokinetic observation Pawel K. Kunicki Poland Institute of Cardiology
8 Tacrolimus whole blood and unbound plasma concentrations early afterheart and lung transplantation Maaike A. Sikma TheNetherlands University Medical Center Utrecht
9 Therapeutic drug monitoring of mycophenolic acid in plasma samples ofpatients with systemic lupus erythematosus and clinical implications Tomasz Pawinski Poland Medical University of Warsaw
10 Towards therapeutic drug monitoring of mycophenolic acid in cicatricialpemphigoid patients Jean-BaptisteWoillard France CHU Limoges, Univ Limoges

P26-7: Oncologic drugs (3): Pharmaometrics, PK/PD, special population

# Presentation Title Name Country Affiliation
1 Bayesian prediction of myelosuppression profiles based on routine clinicaldata after gemcitabine and cisplatin treatment Yugo Chisaki Japan Kyoto Pharmaceutical University
2 Mechanism-based pharmacokinetics and pharmacodynamics neutropeniamodel for irinotecan hydrochloride considering UGT1A1 genotyping TakumiMaruyama Japan Tokyo Women's Medical UniversityHospital
3 Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors(TKIs)after washout in human leukemic K562 cells Tsuyoshi Aoyama Japan Hokkaido University
4 Population pharmacokinetic-pharmacodynamic model of 5-fluorouracil forevaluation of myelosuppression and body weight loss Shinji Kobuchi Japan Kyoto Pharmaceutical Universtiy
5 Assessment of sorafenib-induced toxicities and clinical outcomes basedon therapeutic drug monitoring of soarfenib for patients withhepatocellular carcinoma Satoshi Noda Japan Shiga University of Medical ScienceHospital
6 Meta-analytic population pharmacokinetic analysis to evaluate the effectof renal dysfunction on imatinib clearance in Japanese subjects Sayo Suzuki Japan Keio University
7 A case of gemcitabine and cisplatin chemotherapy in a patient withmetastatic urothelial carcinoma under hemodialysis Taisuke Ezaki Japan Saitama City Hospital
8 Time-serum concentration profiles of cystatin C in lung cancer patientsreceiving CDDP-based chemotherapy TsutomuNakamura Japan Osaka University of PharmaceuticalSciences
9 Beware, the suppliers do not always know what they sell: case report ofdelivered endoxifen isomers Gerd Ackehed Sweden Karolinska University Laboratory
10 High exposure to fludarabine in conditioning prior to allogeneichematopoietic cell transplantation predicts impaired CD4 reconstitutionand lower probability of survival Erik vanMaarseveen TheNetherlands University Medical Center Utrecht

P26-8: Oncologic drugs (4): Pharmacokinetics, TDM practice

# Presentation Title Name Country Affiliation
1 Pharmacokinetics and toxicological evaluation of cyclophosphamide inmice Emiko Miyahara Japan Kagoshima University
2 Pharmacokinetics of cyclophosphamide and its metabolites in pediatrichematopoietic stem cell transplant recipients: a comparative study of twoconditioning regimens and one posttransplantation regimen Takuro Nishikawa Japan Kagoshima University
3 Long term drug interaction between enzalutamide and warfarin afterdiscontinuation of enzalutamide Yukiyoshi Fujita Japan Gunma Prefectural Cancer Center
4 Everolimus pharmacokinetics and toxicity in Japanese patients withadvanced breast cancer MasakiHirabatake Japan Kobe City Medical Center General Hospital
5 Pharmacokinetic analysis of irinotecan and its metabolite to evaluateUGT1A1 and CYP3A activities in patients with UGT1A1 gene polymorphism AkitomoYokokawa Japan Tokyo University of Pharmacy and LifeSciences
6 Development of new monitoring system of antibody drug in humanplasma by liquid chromatography-mass spectrometry using CDR-peptideselective proteolysis nSMOL Noriko Iwamoto Japan Shimadzu Corporation
7 Assessment of renal function of cancer patients for dosing carboplatin Alan Fotoohi Sweden Karolinska Institutet
8 Effectiveness of the multidisciplinary team model in treating colorectalcancer Wen-Li Lin Taiwan Chi Mei Medical Center
9 Population Pharmacokinetics Analysis of Busulfan in Japanese Pediatricand Adult HCT Patients Atsuko Kawazoe Japan Otsuka Pharmaceutical Co., Ltd.
10 The relationship between liver injury and pazopanib trough plasmaconcentration in patients with renal cancer and soft tissue sarcoma Takeshi Aoyama Japan The Cancer Institute Hospital, JapaneseFoundation for Cancer Research

P26-9: Oncologic drugs (5): Pharmacokinetics, TDM practice

# Presentation Title Name Country Affiliation
1 Delayed high-dose methotrexate excretion: is there any relationship withproton pump inhibitors in patients with hematological malignancy? Wei-Jian Ni China Anhui Provincial Hospital, Anhui MedicalUniversity
2 Pharmacokinetics of plasma busulfan using isotope dilution massspectrometry: a pilot study of patients receiving hematopoietic celltransplant in Taiwan Wei-Chi Ku Taiwan Fu Jen Catholic University
3 Dihydromyricetin inhibits human osteosarcoma cells metastasis bysuppressing uPA activation through the ERK1/2 signaling pathway Chia-Hsuan Chou Taiwan Chung Shan Medical University
4 Protodioscin induces mitochondria mediated apoptosis throughendoplasmic reticulum stress and reactive oxygen species-dependentpathway in human cervical cancer cells Chia-Liang Lin Taiwan Chung Shan Medical University
5 Metformin inhibit tumor progression by nickel chloride via p-AKT relatedautophagy Yu-Ting Kang Taiwan Chung-Shan Medical University
6 A-mangostin induces apoptosis and enhances cisplatin sensitivity in humancerivcal cancer stem cell Yi-Hsien Hsieh Taiwan Chung Shan Medical University
7 Melatonin attenuates EGF-induced migration through downregulatingCathepsin S expression in human retinal pigment epithelial ARPE-19 cells Yong-Syuan Chen Taiwan Chung Shan Medical University
8 Synergistic apoptotic effect of Norcantharidin combined with sorafenib inhuman RCC cells in vitro and in vivo Shu-Ching Hsieh Taiwan Chung Shan Medical University
9 Tumor suppressor CYLD as a novel prognostic biomarker in primary breastcancer Hirofumi Jono Japan Kumamoto University Hospital
10 A preliminary study for evaluation of docetaxel exposure and theoccurrence of drug-induced toxicity in a Brazilian population Marina VenzonAntunes Brazil Universidade Feevale

P26-10: Assay of toxicants

# Presentation Title Name Country Affiliation
1 Paper spray ionization for comprehensive drug screening - Are therechances to win a competition with established procedures? Julian A. Michely Germany Saarland University
2 Is a linear triple quadrupole efficient enough to characterize designerbenzodiazepines and their metabolites? Franck Saint-Marcoux France Limoges University Hospital
3 Quantitative screening using liquid chromatography-tandem massspectrometry with MS/MS library based identification Franck Saint-Marcoux France Limoges University Hospital
4 Evaluation of two fully automated immunoassay based tests for themeasurement of Ketamine in human urine and comparison with LC-MS/MS Mariela Marinova Italy University-Hospital of Padua
5 Quantitative analysis of THC and metabolites from multiple matrices usingUPLC-MS/MS for forensic toxicology applications Donald Mason United States ofAmerica Waters Corporation
6 New psychoactive substances 1P-LSD & 1P-ETH-LAD: metabolism anddetectability studied by GC-MS, LC-MSn, and LC-HR-MS/MS Lea Wagmann Germany Saarland University
7 An activity-based screening method for synthetic cannabinoids: fromconcept to application Christophe Stove Belgium Ghent University
8 Extensive toxicological analysis versus routine drugs-of-abuse screening inthe acute patient setting Janine van derSchaar TheNetherlands OLVG Hospital
9 A simple and rapid solid phase extraction method for analysis of THC andTHC-COOH in oral fluid using LC-MS/MS Xiaolei Xie United States ofAmerica Thermo Fisher Scientific
10 Automatic, simultaneous and rapid analysis of 22 drugs of abuse in salivaby on line SPE and UHPLC-MS/MS Mikael Levi Japan Shimadzu Corporation